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Edited by Hans-Diezer KlenkAbstract Hepatitis B virus X protein (HBx) of the hepatitis B
virus is strongly implicated in angiogenesis and metastasis during
hepatocarcinogenesis. Previously, we reported that HBx en-
hances activity of hypoxia-inducible factor-1a (HIF-1a), a
potent transactivator that induces angiogenic factors. Here, we
delineate the structural region of HBx that potentiates HIF-1a.
The carboxy-terminus of HBx increased the stability of HIF-1a
protein, probably through inhibiting interaction with von Hippel-
Lindau protein. Further, the carboxy-terminus of HBx enhanced
the transactivation function of HIF-1a by enhancing its
association with CREB binding protein (CBP). Finally, we
demonstrated the physical association of HBx with the basic
helix–loop–helix/PER–ARNT–SIM domain, the inhibitory do-
main, and the carboxy-terminal transactivation domain of HIF-
1a in vivo.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Hepatitis B virus (HBV) is one of the major causes of acute
and chronic hepatitis, cirrhosis, and hepatocellular carcinoma
(HCC) [1]. Among the HBV proteins, HBV X protein (HBx),
which encodes the X gene of the HBV genome, is indispensable
for viral replication in the natural host and is highly conserved
among mammalian Hepadnaviridae [2]. HBx has been shown
to be expressed both during viral infection and in HBV-asso-
ciated HCC [1,3]. HBx is distributed in the cytoplasm but to
some extent in the nucleus, suggesting an important function
of the protein in modulating wide range of intracellular events
of host cells [1,4,5].* Corresponding author. Fax: +82-2-3408-3768.
E-mail address: molee@sejong.ac.kr (M.-O. Lee).
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carci-
noma; HBx, hepatitis B virus X protein; HIF-1, hypoxia inducible
factor-1; ARNT, aryl hydrocarbon nuclear translocator; VHL, prod-
uct of von Hippel-Lindau; HPH, HIF-1 prolyl hydroxylases; FIH-1,
factor inhibiting HIF-1; CBP, CREB binding protein; HA, hemaglu-
tinin; b-gal, b-galactosidase; GST, glutathione S-transferase; HRE,
hypoxia response element; MAPK, mitogen-activated protein kinase;
bHLH/PAS, basic helix–loop–helix/PER–ARNT–SIM; ODD, oxygen-
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doi:10.1016/j.febslet.2004.10.004Large and advanced HCCs are richly supplied with blood
vessels, indicating that angiogenic factors are involved in the
HBV-associated hepatocarcinogenesis. HBx has been strongly
implicated in angiogenesis and metastasis. Recently, we and
others have shown that HBx enhances protein stability as well
as the transactivation function of hypoxia inducible factor-1a
(HIF-1a), a major transcriptional factor that regulates ex-
pression of angiogenic factors such as vascular endothelial
growth factor (VEGF) [6,7]. HIF-1a forms a heterodimer with
HIF-1b, the previously described aryl hydrocarbon receptor
nuclear translocator (ARNT). HIF-1b is constitutively ex-
pressed, whereas the transcriptional activity of HIF-1a is
tightly regulated by the cellular oxygen concentration [8].
Under normoxic condition, the HIF-1 prolyl hydroxylases
(HPHs) induce hydroxylation of Pro-402 and Pro-564 residues
in the oxygen-dependent degradation domain (ODD) of HIF-
1a, resulting in the binding of HIF-1a to the von-Hippel-
Lindau protein (VHL), the recognition component of an E3
ubiquitin protein ligase. Similarly, ARD1, which functions as
the acetyltransferase, induces acetylation of Lys-532 residue
which enhances interaction of HIF-1a with VHL [9]. Once
bound to VHL, HIF-1a undergoes ubiquitination and prote-
asomal degradation [10,11]. Hydroxylation of Asn-803 within
the C-terminal transactivation domain (CTAD) is carried out
by the factor inhibiting HIF-1 (FIH-1), which binds the
inhibitory domain (ID) and then blocks the association of
HIF-1a with p300 [12]. Under hypoxic condition, HIF-1a ac-
cumulates and associates with the ARNT and the complex
interacts with hypoxia response element (HRE) of target genes
in the nucleus [13,14].
Mutations and deletions in the HBx open reading frame are
frequently found in naturally occurring human HCC [15–22],
which may indicate diﬀerential functions of structural domains
of HBx that contribute to the development of HCC. In the
present investigation, therefore, we analyzed the functional
domain of the HBx that induces transcriptional activity of
HIF-1a to provide further insights on the role of HBx in the
HBV-associated hepatocarcinogensis.2. Materials and methods
2.1. Cell culture
HepG2 (ATCC HB-8065), 293 (ATCC CRL-1573), and NIH3T3
(CRL-1658) cells were obtained from the American Type Culture
Collection. Chang X-34, which expresses HBx under the control of
doxycycline (Doxy)-inducible promoter, was described previously [6].
Cells were maintained in Dulbecco’s modiﬁed Eagle’s mediumblished by Elsevier B.V. All rights reserved.
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5% CO2. Hypoxic condition was induced chemically by treating cells
with 100 lM CoCl2.
2.2. Plasmids and reporter gene assays
The pCMV-Myc-HBx, the truncated deletion constructs of HBx,
i.e., HBxNT (amino acids 1–57) and HBxCT (amino acids 57–154), the
p3XFLAGTM7.1-HIF-1a, the truncated pEBG-HIF-1a constructs,
pGal4-HIF-1a, and pCMV-HA-VHL, were described previously
[6,23,24]. The HRE-Luc, the VEGF promoter-Luc, and the Gal4-tk-
Luc were described previously [6]. Transient transfection and luciferase
assay were performed as described previously [6].
2.3. Western blot analysis and immunoprecipitation
Cells were lysed in a lysis buﬀer and whole cell lysates were obtained
by subsequent centrifugation as described previously [6]. 50 lg of
protein was subjected to 8–15% sodium dodecylsulfate–polyacrylamide
gel electrophoresis and transferred to a polyvinylidene diﬂuoride
membrane (Bio-Rad, Hercules, CA). Membranes were probed with
speciﬁc antibodies against HIF-1a, Myc, hemaglutinin (HA), phos-
phorylated p42/p44, p42/p44, CREB binding protein (CBP) (Santa
Cruz Biotech., Santa Cruz, CA), FLAG (Sigma, St. Louis, MO), or a-
tubulin (Oncogene, Boston, MA). For immunoprecipitation, 500 lg of
whole cell lysates was incubated with 1 lg of anti-HIF-1a, anti-FLAG,
anti-Myc or anti-glutathione S-transferase (GST) and immunoreactive
proteins were detected as described previously [6].Fig. 1. The carboxy-terminus of HBx is essential for enhancing tran-
scriptional activity of HIF-1a. (A) A schematic representation of the
wild-type HBx and the truncated constructs. The shaded and striped
regions represent Kunitz domain homologous region and essential
transactivation domain (TAD), respectively. (B) The HRE-Luc re-
porter gene (0.1 lg) (upper panel) or VEGF promoter-Luc (0.3 lg)
(lower panel) was co-transfected with the indicated amount of the
expression plasmid for HBx, HBxNT, or HBxCT into HepG2 cells.
After 24 h of transfection, the cells were incubated in the presence or
absence of 100 lM CoCl2 for 24 h, and then cell lysates were obtained
and assayed for luciferase activity. Data represent means S.D. of
three independent experiments.3. Results
3.1. The carboxy terminus of HBx induces transcriptional
activity of HIF-1a
Based on the previous observation that the carboxy-termi-
nus of HBx is crucial for the transactivation function
[21,22,25], we constructed two HBx mutants, HBxNT and
HBxCT, as shown in Fig. 1A. First, we carried out reporter
gene analysis by transient transfection of the truncated HBx
expression vectors together with a reporter gene containing
HRE sequences located in the promoter of erythropoietin [6].
Consistent with our previous report, the wild-type HBx in-
duced the HRE reporter dose-dependently (Fig. 1B). To
compare with the wild-type HBx, the HBxNT induced the re-
porter slightly only at the highest dose examined. However, the
HBxCT enhanced the reporter as strongly as the wild-type HBx
(Fig. 1B). Similar results were obtained using the VEGF pro-
moter-Luc reporter (Fig. 1B).
3.2. The carboxy terminus of HBx increases stability of HIF-1a
protein
Next, we examined whether the HBxCT enhanced stability of
HIF-1a protein, since transcriptional activity of HIF-1a is
primarily regulated by the stability of protein. The HBxCT
induced the protein-level of HIF-1a as strongly as the wild-
type HBx, while the HBxNT did not (Fig. 2A). When the
stability of HIF-1a was measured in the presence of cyclo-
heximide (CHX), which blocks new protein synthesis, the
HBxCT blocked degradation of HIF-1a as eﬃciently as the
wild-type HBx, whereas the HBxNT did not at all (Fig. 2B).
Because the stability of HIF-1a is regulated by VHL which
subsequently drives the ubiquitin–proteasomal degradation of
HIF-1a, we examined whether the HBxCT reduced the binding
of HIF-1a to VHL. As in our previous report, when cells were
treated with MG132, which blocks proteasome function, the
binding of HIF-1a and VHL was strong, but the binding was
largely diminished in the presence of hypoxia-mimicking
agent, CoCl2, the wild-type HBx, and the HBxCT (Fig. 2C) [6].We previously demonstrated that HBx induces stability of
HIF-1a through activation of mitogen-activated protein kinase
(MAPK) signaling pathways [6]. When either the wild-type
HBx or the HBxCT was overexpressed, the phosphorylation of
p44/p42 was strongly enhanced, which was in the same pattern
of the expression of HIF-1a (Fig. 2D). The result was consis-
tent with the previous observation that amino acids 58–119 of
HBx were suﬃcient to activate MAPK signaling pathways in
mouse liver [26].
3.3. The carboxy terminus of HBx induces transactivation
function of HIF-1a
Transcriptional activation of HIF-1a can also be achieved
by enhancing transactivation functions of HIF-1a. Therefore,
we examined whether the HBx and its mutants directly en-
hanced transactivation function of HIF-1a using a Gal4-
driven reporter system [6]. Gal4-HIF-1a largely enhanced
Gal4-tk-Luc activity in the presence of either CoCl2 or the
Fig. 2. HBxCT increases the stability of HIF-1a. (A) 293 cells (1 106 cells/well) were seeded in 6-well plates and incubated overnight. The cells were
transfected with 3 lg each of p3XFLAGTM7.1-HIF-1a, pCMV-Myc-HBx, -HBxNT, -HBxCT, and empty vector (EV) with the indicated combination.
After 24 h of transfection, 50 lg of whole cell lysates was analyzed for the expression of the indicated proteins. (B) 293 cells (1 106 cells/well) were
seeded in 6-well plates and incubated overnight. The cells were transfected with 3 lg each of pCMV-Myc-HBx, -HBxNT or -HBxCT. After 24 h of
transfection, the cells were treated with 10 lM CHX for the indicated period. 50 lg of whole cell lysates was analyzed for the expression of the
indicated proteins. (C) NIH3T3 cells (8 105 cells/dish) were seeded in 60-cm2 dishes and incubated overnight. The cells were transfected with 3 lg
pCMV-HA-VHL with 3 lg each of pCMV-Myc-HBx, -HBxCT, or EV. After 1 h of transfection, the cells were treated with 10 lMMG132 for 1 h or
100 lM CoCl2 for 24 h as indicated. 500 lg of whole cell lysates was immunoprecipitated with anti-HIF-1a antibody and then analyzed using anti-
HA antibody. 50 lg of whole cell lysates was analyzed for the expression of the indicated proteins. (D) 293 cells (1 106 cells/well) were seeded in 6-
well plates and incubated overnight. The cells were transfected with 3 lg of each pCMV-Myc-HBx, -HBxNT, -HBxCT, or EV. After 24 h transfection,
50 lg of whole cell lysates was analyzed for the expression of the indicated proteins. The expression of a-tubulin was monitored as a control. One
representative of at least three independent experiments with similar results is shown.
Y.-G. Yoo et al. / FEBS Letters 577 (2004) 121–126 123wild-type HBx. The HBxNT did not induce the reporter, but
the HBxCT induced it as strongly as the wild-type HBx
(Fig. 3A). The association of HIF-1a with coactivator CBP
increased in the presence of either the wild-type HBx or the
HBxCT. These results indicate that the carboxy-terminus of
HBx increases the transactivation of HIF-1a by enhancing the
association of HIF-1a with CBP.3.4. The carboxy-terminus of HBx interacts with HIF-1a
protein
Finally, we examined whether HIF-1a and HBx were
physically associated for the cross-talk. We employed the
Chang X-34, in which the expression of HBx gene is under
control of an inducible Doxy promoter [6]. As shown in
Fig. 4A, HBx was immunoprecipitated with HIF-1a in the
Chang X-34 cells in the presence of Doxy. The speciﬁcity of
the association was demonstrated by the fact that normal
rabbit IgG did not precipitate HBx (Fig. 4A). The result
was conﬁrmed by cotransfection of expression vectors forHBx and HIF-1a in 293 cells. The HBxNT was not asso-
ciated with HIF-1a, whereas the HBxCT strongly interacted
with HIF-1a in vivo (Fig. 4B). To examine which domain
of HIF-1a bound to the HBx protein, six GST-fused HIF-
1a deletion chimeras were tested (Fig. 5A) [23]. Coimmu-
noprecipitation assay showed that HBx bound to all the
GST-fused HIF-1a deletion chimeras except one that con-
tained aa 401–603, which is known to bind VHL and
ARD1 (Fig. 5B).4. Discussion
Previously, we and others reported that HBx enhances
transcriptional activity as well as expression of target genes of
HIF-1a, which could be one of the important mechanisms by
which HBx induces hepatocarcinogenesis [6,7]. Several in vitro
studies indicate that the ﬁrst 50 amino acids at the amino-
terminus of HBx are suﬃcient for cell transformation, while
the carboxy-terminus of HBx is essential for maintaining
Fig. 3. HBxCT increases transactivation function of HIF-1a. (A) The
Gal4-tk-Luc reporter gene (0.2 lg) was co-transfected with the indi-
cated amount of pCMV-Myc-HBx, -HBxNT, or -HBxCT into HepG2
cells. After 24 h of transfection, the cells were incubated with 100 lM
CoCl2 for 24 h, and then cell lysates were obtained and assayed for
luciferase activity. Data represent means S.D. of three independent
experiments. (B) 293 cells (3 106 cells/dish) were seeded in 100-cm2
dishes and incubated overnight. The cells were transfected with 3 lg
p3XFLAGTM7.1-HIF-1a with 3 lg each of pCMV-Myc-HBx,
-HBxCT, or EV. After 24 h of transfection, 500 lg of whole cell lysates
was immunoprecipitated with anti-FLAG antibody and then analyzed
using anti-CBP antibody. 50 lg of whole cell lysates was analyzed for
the expression of indicated proteins. The expression of a-tubulin was
monitored as a control. One representative of at least three indepen-
dent experiments with similar results is shown.
Fig. 4. HBx interacts with HIF-1a protein. (A) Chang X-34 cells
(2 106 cells/dish) were seeded in 100-cm2 dishes and incubated
overnight. The cells were treated with 2 lg/ml Doxy for 24 h or 10 lM
MG132 for 1 h as indicated. 500 lg of whole cell lysates was immu-
noprecipitated with anti-HIF-1a antibody and then analyzed using
anti-HA antibody. 50 lg of whole cell lysates was analyzed for the
expression of indicated proteins (upper panel). Normal rabbit IgG was
used for immunoprecipitation of the whole cell lysates obtained from
the Doxy-treated Chang X-34 cells (lower panel). (B) 293 cells (3 106
cells/dish) were seeded in 100-cm2 dishes and incubated overnight. The
cells were transfected with 3 lg each of pCMV-Myc-HBx, -HBxNT,
-HBxCT or EV. After 1 h of transfection, cells were incubated in the
presence of 100 lM CoCl2 for 24 h as indicated. 500 lg of whole cell
lysates was immunoprecipitated with anti-Myc antibody and then
analyzed using anti-HIF-1a antibody. 50 lg of whole cell lysates was
analyzed for the expression of indicated proteins. The expression of a-
tubulin was monitored as a control. One representative of at least three
independent experiments with similar results is shown.
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suggest that distinct functions of structural domains of HBx
may play diﬀerent roles in the HBV-related hepatocarcino-
genesis. Thus, we investigated the functional domain of HBx
that induces transcriptional activity of HIF-1a and found that
the carboxy-terminus of HBx is important in the transactiva-
tion as well as stability of HIF-1a protein.
Since it was reported that the number of HBV genomes
was low in HBsAg negative tumorous livers of HCC pa-
tients [20,27], the biological relevance of our ﬁndings might
be questioned. However, the expression of HBx in chronic
HBV infection and in progression of HCC remains con-
troversial. Several studies have shown that HBx protein was
detected in a high portion of samples, for instance, 10 of 18
(58.8%) of livers from HCC patients and 69% of samples
from patients with chronic HBV infection [28–32]. The X
gene is the most frequently integrated portion of HBV
DNA found in hepatocyte chromosomes during the devel-
opment of HCC [33]. It has been shown that most, if not
all, HBx isolated from integrated HBV DNA in HCC pa-
tients was in a truncated form [15–22]. Interestingly enough,
Lee et al. demonstrated that hypoxia stimulated the ex-pression of HBx gene in HBV-integrated liver cancer cells
obtained from HCC patients [34]. They also showed that
hypoxia increased the activity of HBV Enhancer1 and
suggested that hypoxia may be a stimulus for the induction
of HBx expression. Since inﬂammatory cytokines such as
IFN-c, TNF, and IL-1b induce stabilization of HIF-1a even
in the absence of hypoxic stress, these cytokines may en-
hance the expression of HBx [35,36]. Taken together, a
signiﬁcant portion of HCC liver expresses HBx, and the
cross-talk between HBx and HIF-1a may play an important
role in the progression of HCCs.
Distinct structural features are required for protein sta-
bility, heterodimerization with ARNT, DNA binding, and
transactivation function of HIF-1a. Factors such as HPH,
VHL, FIH-1, and coactivator CBP/p300 regulate the func-
tion of HIF-1a by direct binding to the speciﬁc structural
domain of HIF-1a. Therefore, the interaction region of each
HIF-1a and HBx may provide a potential molecular mech-
anism of the cross-talk between these two proteins. Indeed,
Fig. 5. HBx interacts with both the amino- and carboxy-terminus of
HIF-1a. (A) Schematic representation of full-length HIF-1a contain-
ing bHLH/PAS, TAD, ODD, and ID [13]. (B) NIH3T3 cells (8 105
cells/dish) were seeded in 60-cm2 dishes and incubated overnight. The
cells were transfected with 3 lg of each the pEBG-HIF-1a constructs
containing the indicated numbered fragment of HIF-1a. 500 lg of
whole cell lysates was immunoprecipitated with anti-GST antibody
and then analyzed using anti-Myc antibody. 50 lg of whole cell lysates
was analyzed for the expression of indicated proteins. The expression
of a-tubulin was monitored as a control. One representative of at least
three independent experiments with similar results is shown.
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helix–loop–helix PER–ARNT–SIM (bHLH/PAS), ID, and
CTAD (Figs. 4 and 5). The bHLH/PAS domain is required
for the heterodimerization with ARNT, which is required for
the optimal DNA binding [37]. HBx, therefore, may enhance
DNA binding of HIF-1 by direct interaction with this re-
gion. Consistent with this result, recently Moon et al. [7]
reported that HBx directly interacted with the bHLH/PAS
domain of HIF-1a in vitro. Also, the binding of HBx with
ID and CTAD in our experiment may suggest that HBx
blocks the association of FIH-1 with HIF-1a, which inhibits
the hydroxylation of Asn-803, and subsequent recruitment of
p300/CBP. In addition, we showed that HBx reduces the
binding of HIF-1a with VHL. This may represent a decrease
in the activity of HPH, which does not require direct asso-
ciation of HBx with ODD domain of HIF-1a (Figs. 2 and
5). HBx was detected predominantly in the cytoplasm;
however, it was also found in the nuclei of positively stained
hepatocytes, either exclusively nuclear or localized both in
the nucleus and cytoplasm within the same cell [38–40].
Further, HBx interacts with a variety of proteins: cytoplas-
mic, nuclear, and those that traﬃc between the cytoplasm
and the nucleus [5]. Therefore, our results may suggest that
HBx has a dual role in that it may enhance stability of HIF-
1a through blocking proteasomal degradation in the cyto-
plasm and it induces transactivation function of HIF-1 by
recruiting coactivator in the nucleus.
In HBV-associated HCC tumor tissues, most of the distal
carboxy-terminus of HBx sequences contains deletion, inser-
tion, or point mutation, which contrasts with the full-lengthHBx isolated from sera and non-tumor tissues [19–22]. Analysis
of these naturally occurringHBxmutants for enhancingHIF-1a
activity and for functions in new vessel formation may provide
new insights on the HBV-associated hepatocarcinogenesis.
Acknowledgements: This study was supported by grants from the
Ministry of Science and Technology (M1-0311-00-0089 and M1-0312-
04-0002).References
[1] Arbuthnot, P., Capovilla, A. and Kew, M. (2000) J. Gastroen-
terol. Hepatol. 15, 357–368.
[2] Zoulim, F., Saputelli, J. and Seeger, C. (1994) J. Virol. 68, 2026–
2030.
[3] Wang, W., London, W.T., Lega, L. and Feitelson, M.A. (1991)
Hepatology 14, 29–37.
[4] Diao, J., Garces, R. and Richardson, C.D. (2001) Cytokine
Growth Factor Rev. 12, 189–205.
[5] Murakami, S. (2001) J. Gastroenterol. 36, 651–660.
[6] Yoo, Y.G., Oh, S.H., Park, E.S., Cho, H., Lee, N., Park, H., Kim,
D.K., Yu, D.Y., Seong, J.K. and Lee, M.O. (2003) J. Biol. Chem.
278, 39076–39084.
[7] Moon, E.J., Jeong, C.H, Jeong, J.W., Kim, K.R., Yu, D.Y.,
Murakami, S., Kim, C.W. and Kim, K.W. (2004) FASEB J. 18,
382–384.
[8] Semenza, G.L. (2001) Trends Mol. Med. 7, 345–350.
[9] Jeong, J.W., Bae, M.K., Ahn, M.Y., Kim, S.H., Sohn, T.K., Bae,
M.H., Yoo, M.A., Song, E.J., Lee, K.J. and Kim, K.W. (2002)
Cell 111, 709–720.
[10] Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway,
R.C. and Conaway, J.W. (2000) Proc. Natl. Acad. Sci. USA 97,
10430–10435.
[11] Tanimoto, K., Makino, Y., Pereira, T. and Poellinger, L. (2000)
EMBO J. 19, 4298–4309.
[12] Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw,
M.L. and Bruick, R.K. (2002) Genes Dev. 16, 1466–1471.
[13] Huang, L.E., Gu, J., Schau, M. and Bunn, H.F. (1998) Proc. Natl.
Acad. Sci. USA 95, 7892–7897.
[14] Kallio, P.J., Wilson, W.J., O’Brien, S., Makino, Y. and Poellinger,
L. (1999) J. Biol. Chem. 274, 6519–6525.
[15] Yamamoto, S., Nakatake, H., Kawamoto, S., Takimoto, M.,
Koshy, R. and Matsubara, K. (1993) Biochem. Biophys. Res.
Commun. 192, 111–118.
[16] Schluter, V., Meyer, M., Hofschneider, P.H., Koshy, R. and
Caselmann, W.H. (1994) Oncogene 9, 3335–3344.
[17] Tsuei, D.J., Hsu, T.Y., Chen, J.Y., Chang, M.H., Hsu, H.C. and
Yang, C.S. (1994) J. Med. Virol. 42, 287–293.
[18] Wei, Y., Etiemble, J., Fourel, G., Vitvitski-Trepo, L. and Buendia,
M.A. (1995) J. Med. Virol. 45, 82–90.
[19] Hsia, C.C., Nakashima, Y. and Tabor, E. (1997) Biochem.
Biophys. Res. Commun. 241, 726–729.
[20] Poussin, K., Dienes, H., Sirma, H., Urban, S., Beaugrand, M.,
Franco, D., Schirmacher, P., Brechot, C. and Paterlini Brechot, P.
(1999) Int. J. Cancer 80, 497–505.
[21] Tu, H., Bonura, C., Giannini, C., Mouly, H., Soussan, P., Kew,
M., Paterlini-Brechot, P., Brechot, C. and Kremsdorf, D. (2001)
Cancer Res. 61, 7803–7810.
[22] Chen, W.N., Oon, C.J., Leong, A.L., Koh, S. and Teng, S.W.
(2000) Biochem. Biophys. Res. Commun. 276, 885–892.
[23] Cho, S., Choi, Y.J., Kim, J.M., Jeong, S.T., Kim, J.H., Kim, S.H.
and Ryu, S.E. (2001) FEBS Lett. 498, 62–66.
[24] Yoo, Y.G. and Lee, M.O. (2004) J. Biol. Chem. 279,
36242–36249.
[25] Gottlob, K., Pagano, S., Levrero, M. and Graessmann, A. (1998)
Cancer Res. 58, 3566–3570.
[26] Nijhara, R., Jana, S.S., Goswami, S.K., Kumar, V. and Sarkar,
D.P. (2001) FEBS Lettt. 504, 59–64.
[27] Paterlini, P. and Brechot, C. (1994) Hepatitis B virus and primary
liver cancer in hepatitis B surface antigen-positive and -negative
patients. in: Primary Liver Cancer: Etiological and Progression
Factors (Brechot, C., Ed.), pp. 167–190, CRC Press, London.
126 Y.-G. Yoo et al. / FEBS Letters 577 (2004) 121–126[28] Moriarty, A.M., Alexander, H., Lerner, R.A. and Thornton, G.B.
(1985) Science 227, 429–433.
[29] Wang, W.L., London, W.T. and Feitelson, M.A. (1991) Cancer
Res. 51, 4971–4977.
[30] Wang, W.L., London, W.T., Lega, L. and Feitelson, M.A. (1991)
Hepatology 14, 29–37.
[31] Zhu, M., London, W.T., Duan, L.X. and Feitelson, M.A. (1993)
Int. J. Cancer 55, 571–576.
[32] Hoare, J., Henkler, F., Dowling, J.J., Errington, W., Goldin, R.D.,
Fish, D. and McGarvey, M.J. (2001) J. Med. Virol. 64, 419–426.
[33] Koike, K., Moriya, K., Iino, S., Yotsuyanagi, H., Endo, Y.,
Miyamura, T. and Kurokawa, K. (1994) Hepatology 19, 810–819.
[34] Lee, S.W., Lee, Y.M., Bae, S.K., Murakami, S., Yun, Y. and Kim,
K.W. (2000) Biochem. Biophys. Res. Commun. 268, 456–461.[35] Scharte, M., Han, X., Bertges, D.J., Fink, M.P. and Delude,
R.L. (2003) Am. J. Physiol. Gastrointest. Liver Physiol. 284,
G373–384.
[36] Jung, Y.J., Isaacs, J.S., Lee, S., Trepel, J. and Neckers, L. (2003)
FASEB J. 17, 2115–2117.
[37] Jiang, B.H., Rue, E., Wang, G.L., Roe, R. and Semenza, G.L.
(1996) J. Biol. Chem. 271, 17771–17778.
[38] Hohne, M., Schaefer, S., Seifer, M., Feitelson, M.A., Paul, D. and
Gerlich, W.H. (1990) EMBO J. 9, 1137–1145.
[39] Zentgraf, H., Herrmann, G., Klein, R., Schranz, P., Loncarevic,
I., Herrmann, D., Hubner, K. and Schroder, C.H. (1990)
Oncology 47, 143–148.
[40] Doria, M., Klein, N., Lucito, R. and Schneider, R.J. (1995)
EMBO J. 14, 4747–4757.
